Your browser doesn't support javascript.
loading
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Motzer, Robert; Porta, Camillo; Alekseev, Boris; Rha, Sun Young; Choueiri, Toni K; Mendez-Vidal, Maria Jose; Hong, Sung-Hoo; Kapoor, Anil; Goh, Jeffrey C; Eto, Masatoshi; Bennett, Lee; Wang, Jinyi; Pan, Jie Janice; Saretsky, Todd L; Perini, Rodolfo F; He, Cixin Steven; Mody, Kalgi; Cella, David.
Afiliação
  • Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.
  • Porta C; Interdisciplinary Department of Medicine, University of Bari 'A Moro', Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Pavia, Pavia, Italy.
  • Alekseev B; Department of Oncourology, P A Herzen Moscow Oncological Research Institute, Moscow, Russia.
  • Rha SY; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.
  • Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Mendez-Vidal MJ; Maimonides Institute for Biomedical Research of Cordoba Hospital, Universitario Reina Sofía, Córdoba, Spain.
  • Hong SH; Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
  • Kapoor A; McMaster University, Hamilton, ON, Canada.
  • Goh JC; ICON Research, South Brisbane and Queensland University of Technology, Brisbane, QLD, Australia.
  • Eto M; Kyushu University, Fukuoka, Japan.
  • Bennett L; RTI Health Solutions, Research Triangle Park, NC, USA.
  • Wang J; RTI Health Solutions, Research Triangle Park, NC, USA.
  • Pan JJ; Eisai, Nutley, NJ, USA.
  • Saretsky TL; Merck & Co, Kenilworth, NJ, USA.
  • Perini RF; Merck & Co, Kenilworth, NJ, USA.
  • He CS; Eisai, Nutley, NJ, USA.
  • Mody K; Eisai, Nutley, NJ, USA.
  • Cella D; Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA.
Lancet Oncol ; 23(6): 768-780, 2022 06.
Article em En | MEDLINE | ID: mdl-35489363
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article